19 May 2013
Keywords: merck, alendronate, filing, usa, soon, co, bisphosphonate
Article | 27 February 1995
Merck & Co's bisphosphonate compound alendronate has been shown to
increase bone density in the spine by 6.8% over a three-year study,
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 February 1995
17 May 2013
© 2013 thepharmaletter.com